知镜 Cognispect · 医学文献与研究工作台

Orthopnea From Phrenic Nerve Palsy After Ciltacabtagene Autoleucel CAR T-Cell Therapy in a Patient With Multiple Myeloma.

Fitzgerald EC, Altshuler D, Tanner AM, Gupta S, Lin Y.
Journal of the advanced practitioner in oncology · 2026-09-01 · PMID 42991680

文献摘要

Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of relapsed/refractory multiple myeloma (MM), particularly with the advent of ciltacabtagene autoleucel (cilta-cel). As its clinical use expands, novel and delayed toxicities are increasingly recognized. We report the first documented case of bilateral phrenic nerve palsy following cilta-cel infusion, presenting with acute dyspnea and profound orthopnea. Diagnostic evaluation was challenged by the patient's inability to tolerate the supine position, delaying definitive imaging. Ultimately, diaphragmatic ultrasound and phrenic nerve conduction studies confirmed isolated bilateral phrenic neuropathy without evidence of myopathy or cervical radiculopathy. The patient was treated with intravenous immunoglobulin (IVIG), high-dose corticosteroids, and prolonged bilevel positive airway pressure (BiPAP) support. Despite this neurologic complication, he achieved minimal residual disease (MRD)-negative complete remission. This case highlights an emerging neurotoxicity of cilta-cel, underscores the importance of early recognition of diaphragmatic dysfunction, and outlines diagnostic and management considerations for advanced practice providers (APPs).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。